Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May;117(5):1130-6.
doi: 10.1172/JCI32136.

Harnessing the immune system to treat cancer

Nina Bhardwaj  1
Affiliations
Review

Harnessing the immune system to treat cancer

Nina Bhardwaj. J Clin Invest. 2007 May.

Abstract

A major challenge for the immune system is to recognize and eliminate cells undergoing carcinogenesis. Immune defense against tumors is complex. It can be mediated early by the innate immune system (i.e., phagocytes, NK cells, NKT cells, cytokines, and complement proteins) and later by the adaptive immune system (i.e., B cells and T cells). The eight articles in this Review series on tumor immunology discuss the mechanisms underlying immune surveillance of tumors, the regulation of carcinogenesis by immune inflammatory mediators, current approaches to controlling tumor growth through immunotherapy, and novel targets of immunotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Some of the immunological factors discussed in this Review series that affect tumor development.
Cells of both the innate and adaptive arms of the immune system can mediate antitumor immunity, including CTLs, CD4+ T cells, B cells, and NK cells. However, as tumors progress, they often develop ways in which to escape immune recognition. For example, they can induce the production of proinflammatory cytokines, the expression of IDO by APCs, and the differentiation of Tregs and various suppressor cells of myeloid origin. TAM, tumor-associated macrophage.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ehrlich P. Über den jetzigen Stand der Karzinomforschung [In German]. Ned. Tijdschr. Geneeskd. 1909;5:273–290.
    1. Burnet M. Immunological factors in the process of carcinogenesis. Br. Med. Bull. 1964;20:154–158. - PubMed
    1. Thomas, L. 1959. Reactions to homologous tissue antigens in relation to hypersensitivity [discussion]. InCellular and humoral aspects of the hypersensitive states. H.S. Lawrence, editor. Hoeber-Harper. New York, New York, USA. 529–532.
    1. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002;3:991–998. - PubMed
    1. Shankaran V., et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. - PubMed